
Non-mevalonate pathway

The non-mevalonate pathway—also appearing as the mevalonate-independent pathway and the 2-"C"-methyl--erythritol 4-phosphate/1-deoxy--xylulose 5-phosphate (MEP/DOXP) pathway—is an alternative metabolic pathway for the biosynthesis of the isoprenoid precursors isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). The currently preferred name for this pathway is the MEP pathway, since MEP is the first committed metabolite on the route to IPP.
Isoprenoid precursor biosynthesis.
The classical mevalonate pathway or HMG-CoA reductase pathway is a metabolic pathway from the biosynthesis of isoprenoid precursors present in most higher eukaryotes and some bacteria. It is important for the production of IPP and DMAPP, which serve as the basis for the biosynthesis of isoprenoid (terpenoid) molecules used in processes as diverse as protein prenylation, cell membrane maintenance, the synthesis of hormones, protein anchoring and "N"-glycosylation.
Bacteria, plants, and apicomplexan protozoa—such as malaria parasites—are able to produce isoprenoid precursors using an alternative pathway, the MEP pathway, which is a "non-mevalonate pathway." In the case of plants and certain protozoa, the biosynthesis of IPP/DMAPP takes place in plastid organelles. Plants synthesise isoprenoid precursors using the mevalonate pathway in the cytoplasm and using the MEP pathway in their chloroplasts. Bacteria such as the model organism "Escherichia coli" have been engineered for co-expressing both the MEP and the mevalonate pathway. Distribution of the metabolic fluxes between the MEP and the mevalonate pathway can be studied using 13C-glucose isotopomers. Bacteria that use the MEP pathway include important pathogens such "Mycobacterium tuberculosis".
Reactions.
The reactions of the non-mevalonate pathway are as follows, taken primarily from Eisenreich and co-workers, except where the bold labels are additional local abbreviations to assist in connecting the table to the scheme above:
Inhibition and other pathway research.
DXP reductoisomerase (also known as: DXR, DOXP reductoisomerase, IspC, MEP synthase), is a key enzyme in the MEP pathway. It can be inhibited by the natural product 
fosmidomycin, which is under study as a starting point to develop a candidate antibacterial or antimalarial drug.
The intermediate, HMB-PP, is a natural activator of human Vγ9/Vδ2 T cells, the major γδ T cell population in peripheral blood, and cells that "play a crucial role in the immune response to microbial pathogens".